LimmaTech Biologics AG is a Swiss-based clinical stage biopharmaceutical company. We are advancing our proprietary vaccine pipeline to halt the increasing threat of global infections due to emerging antibiotic resistance (AMR) and sexually transmitted diseases.In addition to our proprietary research, we also develop vaccines together with GSK.

LimmaTech Biologics AG

Euro

Google Maps

Swisscom

Hostpoint

Michael Kowarik

CSO & Co-Founder

Paul Wolfrom

Co-Founder & CFO

Franz-Werner Haas

Biotechnology Companies (Top 10K)

Biotechnology Companies With Fewer Than 50 Employees (Top 10K)

Biotechnology Companies With More Than 10 Employees (Top 10K)

Europe Early Stage Companies With More Than 10 Employees

LimmaTech Biologics AG is a clinical-stage biopharmaceutical company.

Adjuvant Capital

AXA Investment Managers

Repair Impact Fund

Series A - LimmaTech Biologics

Schlieren

Zurich

Switzerland

Europe

LimmaTech Biologics

Valneva and LimmaTech Announce First Vaccination in Phase 2b Human Challenge Study of Tetravalent Shigella Vaccine Candidate S4V2

LimmaTech Biologics Adds Additional $3 Million in Series A Second Closing Bringing Total Raised to $40 Million

LimmaTech Biologics Raises Additional $3M in Series A

Engineered and Fully-Functional Customized Glycoproteins

LimmaTech Biologics Raises $37M in Series A Funding

India

Asia

LimmaTech Biologics AG is a Swiss-based clinical stage biopharmaceutical company pioneering vaccine development technologies to build a pipeline of vaccine programs to protect against and prevent severe infections caused by pathogens that have become resistant to antimicrobial treatments.

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Nov 18, 2024 2:12 PM	f91e5791
crunchbase profile	general	Nov 19, 2024 10:37 AM	1097e72a
li profile	general	Feb 1, 2024 12:01 PM	05b00d65
translate crunchbase fundingrounds	general	Nov 19, 2024 10:56 AM	5193525c
peers	general	Feb 1, 2024 12:01 PM	ae04260c
news basic	general
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:LMTBIO

LimmaTech Biologics AG